Serum Antimullerian Hormone Levels Among Epileptic Patients

Sponsor
Near East University, Turkey (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05066360
Collaborator
(none)
60
1
2
7.8
7.7

Study Details

Study Description

Brief Summary

The production of AMH starts in granulosa cells before birth and the levels within the serum decreases towards the menapouse. The levels of AMH do not change throughout the menstruation cycle hovewer, it can be affected in cases related to body mass index (BMI), polycyctic ovarian syndrome (PCOS). The lower levels of AMH had been documented after ovarian surgery, radiotheraphy and chemotheraphy. AMH is a member of Transforming Growth Faktor β (TGF- β ) and it has receptors in brain structures including hyppocammpus. It is highly active neurophysiologically and it has a protective effect against N-methyl-D -aspartate related neuronal injury that is demonstrated both in vivo and in vitro studies. As a result, being a neuroactive hormone; AMH may have an effect on seizures within epileptic patients or serum AMH levels may be effected in epileptic patients when compared with healthy ones.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: serum antimullerian hormone
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
two groups (epileptic and healthy participants)two groups (epileptic and healthy participants)
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Investigation of Serum Antimullerian Hormone Levels in Adolescent Epilepsy Patients
Actual Study Start Date :
Jul 2, 2021
Anticipated Primary Completion Date :
Feb 20, 2022
Anticipated Study Completion Date :
Feb 25, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: participants with epilepsy

healthy, menstruating females between 12-18 ages

Diagnostic Test: serum antimullerian hormone
serum antimullerian hormone will be analyzed for all participants

Other: healthy participants

epileptic, menstruating females between 12-18 ages

Diagnostic Test: serum antimullerian hormone
serum antimullerian hormone will be analyzed for all participants

Outcome Measures

Primary Outcome Measures

  1. serum anti-mullerian hormone levels [baseline, at the time of examination]

    The comparison of serum levels of anti-mullerian hormone between epileptic and healthy groups

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 18 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy and epileptic volunteer females

  • Ages between 12-18

  • After menarche

Exclusion Criteria:
  • ovarian surgery,

  • history of radiotherapy

  • history of chemotherapy,

  • before menarche

Contacts and Locations

Locations

Site City State Country Postal Code
1 Near East University Faculty of Medicine Nicosia Cyprus 99138

Sponsors and Collaborators

  • Near East University, Turkey

Investigators

  • Principal Investigator: ALİ ÖZAY, Assoc Prof, Near East University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ali Cenk, Medical Doctor, Associate Professor, Near East University, Turkey
ClinicalTrials.gov Identifier:
NCT05066360
Other Study ID Numbers:
  • AMH
First Posted:
Oct 4, 2021
Last Update Posted:
Oct 4, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ali Cenk, Medical Doctor, Associate Professor, Near East University, Turkey
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 4, 2021